The minimal amount of starting DNA for Agilent’s hybrid capture-based targeted massively parallel sequencing

Targeted capture massively parallel sequencing is increasingly being used in clinical settings, and as costs continue to decline, use of this technology may become routine in health care. However, a limited amount of tissue has often been a challenge in meeting quality requirements. To offer a pract...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Jongsuk, Son, Dae-Soon, Jeon, Hyo-Jeong, Kim, Kyoung-Mee, Park, Gahee, Ryu, Gyu Ha, Park, Woong-Yang, Park, Donghyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879621/
https://www.ncbi.nlm.nih.gov/pubmed/27220682
http://dx.doi.org/10.1038/srep26732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879621/
https://www.ncbi.nlm.nih.gov/pubmed/27220682
http://dx.doi.org/10.1038/srep26732

Ejemplares similares